The Global Alliance for Tuberculosis Drug Development - Accomplishments and future directions

Clinics in Chest Medicine

Volumn 26, Issue 2, 2005, Pages 341-347

  Gardner, Charles A ^a   Acharya, Tara ^a   Pablos Méndez, Ariel ^b  

^a ROCKEFELLER FOUNDATION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CARBOXYLIC ACID DERIVATIVE; ETHAMBUTOL; GATIFLOXACIN; ISOCITRATE LYASE; ISONIAZID; LL 3858; MACROLIDE; METHYLTRANSFERASE INHIBITOR; MOXIFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PLEUROMUTILIN; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 17044392623     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2005.02.008     Document Type: Review

References (14)

1. World Health Organization. Fact sheet no. 104, revised March 2004 2004 World Health Organization Geneva (Switzerland)
2. Médecins sans Frontières Campaign for access to essential medicines. Running out of breath? Available at: http://www. doctorswithoutborders.org/publications/reports/2004/tbreport_2004.pdf Accessed March 4, 2005
3. World Health Organization. WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999-2002. Anti-tuberculosis drug resistance in the world (third global report) Available at: http://www.tballiance.org/ MDR_report/WHO_MDRTB_report.pdf Accessed March 4, 2005
4. Global Alliance for TB Drug Development The economics of TB drug development, October 2001 2001 Global Alliance for TB Drug Development New York
5. Global Alliance for TB Drug Development Overview of the TB Alliance program Available at: http//www.tballiance.org Accessed March 4, 2005
6. A. Pablos-Méndez for the Working Alliance for TB Drug Development The declaration of Cape Town Int J Tuberc Lung Dis 4 6 2000 489 490
7. E.L. Nuermberger, T. Yoshimatsu, and S. Tyagi Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am J Respir Crit Care Med 169 3 2004 421 426
8. Astrazeneca Astrazeneca opens multi-million dollar Indian research facility to find new treatments for tuberculosis [press release, June 2, 2003] Available at: http://www.astrazeneca.com/pressrelease/497.aspx Accessed March 4, 2005
9. Novartis Novartis Institute for Tropical Diseases opens in Singapore's state-of-the-art Biopolis research facility. Novartis special report Available at: http://www.novartis.com/special/nitd_opening_pr.shtml Accessed March 4, 2005
10. Foundation for Innovative New Diagnostics (FIND) Available at: http://www.finddiagnostics.org
11. Internal strategic planning document 1998 The Rockefeller Foundation New York
12. T.G. Evans Health-related global public goods: initiatives of the Rockefeller Foundation 2002 Available at: http://www.undp.org/ods/monterrey- papers/evans.pdf Accessed March 4, 2005
13. C. Wheeler, and S. Berkley Initial lessons from public-private partnerships in drug and vaccine development Bull World Health Organ 79 no. 8 2001 728 734
14. The Rockefeller Foundation Partnering to develop new products for diseases of poverty-one donor's perspective 2004 Available at: http://www.rockfound.org Accessed March 8, 2005